25Jul 2023
Off-Label Use of Systemic Calcineurin Inhibitors Tacrolimus and Voclosporin for Dermatologic Conditions

Off-Label Use of Systemic Calcineurin Inhibitors Tacrolimus and Voclosporin for Dermatologic Conditions

Tacrolimus, 100x more potent than cyclosporine, effectively suppresses T-cell activation and improves blood pressure and lipid profiles. With better intestinal absorption and predictable bioavailability, it's promising for psoriasis, atopic dermatitis, and more. Voclosporin, a new calcineurin inhibitor, has improved tolerability and dosing. Healthcare providers can consider tacrolimus for treatment-resistant cases with cardiovascular risk factors or inflammatory bowel disease. Voclosporin merits consideration for lupus nephritis, but more research is needed for other skin conditions.

  • #dermatology

Like

Save

Share